Lantern Pharma names CFO David Margrave interim CEO
LTRN•Lantern Pharma appointed CFO David Margrave interim CEO effective November 16, 2026, after Panna Sharma resigned as president, CEO and board member effective November 15. Margrave will serve until a permanent CEO is appointed, and the board plans to begin a successor search.
1. CEO transition
Lantern Pharma appointed Chief Financial Officer David Margrave interim CEO effective November 16, 2026. Panna Sharma resigned as president, CEO and a board member effective November 15. Margrave will serve until a permanent CEO is appointed, and the board plans to promptly begin a successor search.




